Candel Therapeutics (CADL) has shared an update.
Candel Therapeutics, Inc. is set to make a significant impact at the upcoming 2024 American Society of Clinical Oncology Annual Meeting with two poster presentations highlighting their latest clinical trials. They will showcase promising feasibility and tolerance data from a phase 1 trial of CAN-3110 in treating recurrent high-grade glioma and reveal encouraging overall survival data from a phase 2 trial of CAN-2409 combined with immune therapies in advanced non-small cell lung cancer patients. These insights could stir investor interest and optimism in the company’s innovative cancer treatments.
Find detailed analytics on CADL stock on TipRanks’ Stock Analysis page.
